|

Effect of Flozin (dapagliflozin) Administration on Myocardial and Peripheral Vascular Remodeling

RECRUITINGSponsored by Poznan University of Medical Sciences
Actively Recruiting
SponsorPoznan University of Medical Sciences
Started2023-03-10
Est. completion2026-02-28
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06679179

Summary

The aim of this study is to assess the effect of treatment with flozin (dapagliflozin 10mg once a day) on haemodynamic parameters and myocardial and peripheral vascular remodeling in patients with NYHA class II-III heart failure.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* diagnosed heart failure NYHA class II and III
* consent to participate in the study
* patients should already be receiving treatment with an ACE inhibitor or sacubitril/valsartan or sartans, a beta-blocker, and an MRA, and should start on SGLT2i as part of therapy enhancement

Exclusion Criteria:

\-

Conditions2

Heart DiseaseHeart Failure

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.